Peter D Cole1, Kathleen M McCarten2, Qinglin Pei3, Menachem Spira4, Monika L Metzger5, Richard A Drachtman6, Terzah M Horton7, Rizvan Bush8, Susan M Blaney7, Brenda J Weigel9, Kara M Kelly10. 1. Department of Pediatrics, Albert Einstein College of Medicine, Bronx, NY, USA; Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Electronic address: Peter.Cole@Rutgers.edu. 2. Imaging and Radiation Oncology Core Rhode Island, Lincoln, RI, USA. 3. Department of Biostatistics, University of Florida, Gainesville, FL, USA; Children's Oncology Group, Statistics and Data Center, Monrovia, CA, USA. 4. The Children's Hospital at Montefiore, Bronx, NY, USA. 5. St. Jude Children's Research Hospital, Memphis, TN, USA. 6. Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 7. Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA. 8. Children's Oncology Group, Statistics and Data Center, Monrovia, CA, USA. 9. University of Minnesota, Minneapolis, MN, USA. 10. Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.
Abstract
BACKGROUND: Patients with primary refractory Hodgkin's lymphoma or early relapse have a poor prognosis. Although many salvage regimens have been developed, there is no standard of care. Brentuximab vedotin and gemcitabine have been shown to be active in patients with relapsed or refractory Hodgkin's lymphoma when used as monotherapy, and each has been successfully used in combination with other agents. Preclinical data suggest that brentuximab vedotin can sensitise lymphoma cells to gemcitabine, supporting the use of the combination. We aimed to define the safety and efficacy of brentuximab vedotin with gemcitabine in children and young adults with primary refractory Hodgkin's lymphoma or early relapse. METHODS: In this Children's Oncology Group, multicentre, single-arm, phase 1-2 trial, we recruited patients with Hodgkin's lymphoma from hospitals across the USA and Canada. Eligible patients were aged younger than 30 years, had no previous brentuximab vedotin exposure, and had primary refractory disease or relapse of less than 1 year from completion of initial treatment. Each 21-day cycle consisted of 1000 mg/m2 intravenous gemcitabine on days 1 and 8 and intravenous brentuximab vedotin on day 1 at 1·4 mg/kg or 1·8 mg/kg. The primary objectives were to establish the recommended phase 2 dose of brentuximab vedotin in this combination, the safety of the combination, and the proportion of patients who achieved a complete response among those treated at the recommended phase 2 level, within four cycles of treatment. This trial is registered with ClinicalTrials.gov, number NCT01780662. FINDINGS: Between Feb 5, 2013, and Aug 19, 2016, 46 patients were enrolled, including one who was found to be ineligible, in the two phases of the study. The recommended phase 2 dose of brentuximab vedotin was 1·8 mg/kg in combination with gemcitabine 1000 mg/m2. 24 (57%) of 42 evaluable patients (95% CI 41-72) given this dose level had a complete response within the first four cycles of treatment. Four (31%) of 13 patients with a partial response or stable disease had all target lesions with Deauville scores of 3 or less after cycle 4. By modern response criteria, these were also complete responses (total number with complete response 28 [67%] of 42 [95% CI 51-80]). The most common grade 3-4 adverse events in all 42 participants treated at the recommended phase 2 dose were neutropenia (15 [36%]), rash (15 [36%]), transaminitis (9 [21%]), and pruritus (4 [10%]). There were no treatment-related deaths. INTERPRETATION: Brentuximab vedotin with gemcitabine is a safe combination treatment with a tolerable toxicity profile for patients with primary refractory Hodgkin's lymphoma or high-risk relapse. The preliminary activity of this combination shown in this trial warrants further investigation in randomised controlled trials. FUNDING: National Institutes of Health and the St. Baldrick's Foundation.
BACKGROUND:Patients with primary refractory Hodgkin's lymphoma or early relapse have a poor prognosis. Although many salvage regimens have been developed, there is no standard of care. Brentuximabvedotin and gemcitabine have been shown to be active in patients with relapsed or refractory Hodgkin's lymphoma when used as monotherapy, and each has been successfully used in combination with other agents. Preclinical data suggest that brentuximabvedotin can sensitise lymphoma cells to gemcitabine, supporting the use of the combination. We aimed to define the safety and efficacy of brentuximabvedotin with gemcitabine in children and young adults with primary refractory Hodgkin's lymphoma or early relapse. METHODS: In this Children's Oncology Group, multicentre, single-arm, phase 1-2 trial, we recruited patients with Hodgkin's lymphoma from hospitals across the USA and Canada. Eligible patients were aged younger than 30 years, had no previous brentuximabvedotin exposure, and had primary refractory disease or relapse of less than 1 year from completion of initial treatment. Each 21-day cycle consisted of 1000 mg/m2 intravenous gemcitabine on days 1 and 8 and intravenous brentuximabvedotin on day 1 at 1·4 mg/kg or 1·8 mg/kg. The primary objectives were to establish the recommended phase 2 dose of brentuximabvedotin in this combination, the safety of the combination, and the proportion of patients who achieved a complete response among those treated at the recommended phase 2 level, within four cycles of treatment. This trial is registered with ClinicalTrials.gov, number NCT01780662. FINDINGS: Between Feb 5, 2013, and Aug 19, 2016, 46 patients were enrolled, including one who was found to be ineligible, in the two phases of the study. The recommended phase 2 dose of brentuximabvedotin was 1·8 mg/kg in combination with gemcitabine 1000 mg/m2. 24 (57%) of 42 evaluable patients (95% CI 41-72) given this dose level had a complete response within the first four cycles of treatment. Four (31%) of 13 patients with a partial response or stable disease had all target lesions with Deauville scores of 3 or less after cycle 4. By modern response criteria, these were also complete responses (total number with complete response 28 [67%] of 42 [95% CI 51-80]). The most common grade 3-4 adverse events in all 42 participants treated at the recommended phase 2 dose were neutropenia (15 [36%]), rash (15 [36%]), transaminitis (9 [21%]), and pruritus (4 [10%]). There were no treatment-related deaths. INTERPRETATION:Brentuximabvedotin with gemcitabine is a safe combination treatment with a tolerable toxicity profile for patients with primary refractory Hodgkin's lymphoma or high-risk relapse. The preliminary activity of this combination shown in this trial warrants further investigation in randomised controlled trials. FUNDING: National Institutes of Health and the St. Baldrick's Foundation.
Authors: Paul D Harker-Murray; Richard A Drachtman; David C Hodgson; Allen Russell Chauvenet; Kara M Kelly; Peter David Cole Journal: Pediatr Blood Cancer Date: 2013-11-08 Impact factor: 3.167
Authors: C G Cerveny; C-L Law; R S McCormick; J S Lenox; K J Hamblett; L E Westendorf; A K Yamane; J M Petroziello; J A Francisco; A F Wahl Journal: Leukemia Date: 2005-09 Impact factor: 11.528
Authors: C H Moskowitz; J R Bertino; J R Glassman; E E Hedrick; S Hunte; N Coady-Lyons; D B Agus; A Goy; J Jurcic; A Noy; J O'Brien; C S Portlock; D S Straus; B Childs; R Frank; J Yahalom; D Filippa; D Louie; S D Nimer; A D Zelenetz Journal: J Clin Oncol Date: 1999-12 Impact factor: 44.544
Authors: K A Blum; S-H Jung; J L Johnson; T S Lin; E D Hsi; D M Lucas; J C Byrd; B D Cheson; N L Bartlett Journal: Ann Oncol Date: 2010-04-27 Impact factor: 32.976
Authors: Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: A Santoro; H Bredenfeld; L Devizzi; H Tesch; V Bonfante; S Viviani; F Fiedler; H S Parra; C Benoehr; M Pacini; G Bonadonna; V Diehl Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Wouter J Plattel; Zainab N D Alsada; Gustaaf W van Imhoff; Arjan Diepstra; Anke van den Berg; Lydia Visser Journal: Br J Haematol Date: 2016-09-09 Impact factor: 6.998
Authors: AnnaLynn M Williams; Sedigheh Mirzaei Salehabadi; Mengqi Xing; Nicholas S Phillips; Matthew J Ehrhardt; Rebecca Howell; Yutaka Yasui; Kevin C Oeffinger; Todd Gibson; Eric J Chow; Wendy Leisenring; Deokumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kevin R Krull Journal: Blood Date: 2022-05-19 Impact factor: 25.476
Authors: Matthew G Mei; Hun Ju Lee; Joycelynne M Palmer; Robert Chen; Ni-Chun Tsai; Lu Chen; Kathryn McBride; D Lynne Smith; Ivana Melgar; Joo Y Song; Kimberley-Jane Bonjoc; Saro Armenian; Mary Nwangwu; Peter P Lee; Jasmine Zain; Liana Nikolaenko; Leslie Popplewell; Auayporn Nademanee; Ammar Chaudhry; Steven Rosen; Larry Kwak; Stephen J Forman; Alex F Herrera Journal: Blood Date: 2022-06-23 Impact factor: 25.476
Authors: Ilia N Buhtoiarov; Nkechi I Mba; Crystal D L Santos; Kathleen M McCarten; Monika L Metzger; Qinglin Pei; Rizvan Bush; Kayla Baker; Kara M Kelly; Peter D Cole Journal: Pediatr Blood Cancer Date: 2022-03-26 Impact factor: 3.838
Authors: Scott Moerdler; Michelle Ewart; Debra L Friedman; Kara Kelly; Qinglin Pei; Mou Peng; XingXing Zang; Peter D Cole Journal: Leuk Lymphoma Date: 2020-10-28